Neogen and Pfizer see significant market and institutional activity

Neogen Corporation has seen significant market activity, with shares jumping 8.0% to $12.92 following its inclusion on a healthcare stock watchlist. Guggenheim has raised its price target for Neogen from $12.00 to $14.00. The company is scheduled to release its fiscal 2027 first-quarter results on October 6, 2026, with an expected revenue consensus of approximately $207.90 million. An Investor Day in New York is also planned for October 7, 2026, to discuss strategic transformation and growth.

Separately, Pfizer Inc. has seen varied institutional activity. Canandaigua National Trust Co of Florida recently purchased 42,478 shares in the third quarter. Other institutional investors, including Russell Investments Group Ltd. and Handelsbanken Fonder AB, have also modified or increased their holdings. Pfizer faces upcoming patent expirations for key drugs such as Eliquis and Ibrance toward the end of the decade, though the company is looking to its pipeline to offset potential revenue losses.